Company intelligence / Profile preview

KGEC

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

KGEC (Korea Genome & Epitome Center) is a South Korean biotechnology company specializing in advanced genome and epigenome editing technologies. The company focuses on developing therapeutic solutions for complex diseases by modulating gene expression without altering the underlying DNA sequence, a process known as epigenetic editing. Their research and development efforts are primarily directed toward oncology and rare genetic disorders, leveraging proprietary CRISPR-based tools and small molecule modulators. KGEC aims to provide precision medicine through its innovative platform that targets specific epigenetic markers to treat chronic and life-threatening conditions.

Therapeutic areas: OncologyRare Diseases
Modalities: Gene therapyCRISPR-based therapySmall molecule
Industry: Biotech

Partnerships

ToolGenSeoul National University

Beyond the preview

Go deeper on KGEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KGEC.

Explore the full profile